Analysts at StockNews.com started coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Rating) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Several other research firms have also recently commented on ACRX. HC Wainwright cut AcelRx Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, March 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, March 11th.
NASDAQ ACRX opened at $0.19 on Wednesday. The stock has a market cap of $28.54 million, a PE ratio of -0.72 and a beta of 0.71. AcelRx Pharmaceuticals has a fifty-two week low of $0.16 and a fifty-two week high of $1.55. The business has a 50 day moving average price of $0.23 and a two-hundred day moving average price of $0.36.
Several institutional investors and hedge funds have recently modified their holdings of the company. D. E. Shaw & Co. Inc. increased its holdings in shares of AcelRx Pharmaceuticals by 12.3% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 3,721,586 shares of the specialty pharmaceutical company’s stock valued at $2,085,000 after purchasing an additional 407,507 shares during the period. Values First Advisors Inc. boosted its stake in AcelRx Pharmaceuticals by 23.7% during the first quarter. Values First Advisors Inc. now owns 642,515 shares of the specialty pharmaceutical company’s stock valued at $183,000 after buying an additional 123,241 shares in the last quarter. Millennium Management LLC boosted its stake in AcelRx Pharmaceuticals by 40.1% during the fourth quarter. Millennium Management LLC now owns 334,248 shares of the specialty pharmaceutical company’s stock valued at $187,000 after buying an additional 95,716 shares in the last quarter. apricus wealth LLC bought a new position in AcelRx Pharmaceuticals during the fourth quarter valued at about $73,000. Finally, Cornerstone Capital Inc. bought a new position in AcelRx Pharmaceuticals during the fourth quarter valued at about $45,000. 23.12% of the stock is currently owned by institutional investors.
AcelRx Pharmaceuticals Company Profile (Get Rating)
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures.
- Get a free copy of the StockNews.com research report on AcelRx Pharmaceuticals (ACRX)
- This Still Isn’t A Buyable Bottom For Stocks
- Should Silver Stocks Be A Part Of Your Portfolio?
- ABM Industries, A Clean Play For Dirty Economic Times
- Two Defensive Stocks To Get Aggressive With
- Don’t Get Too Bullish On Lennar Even Though It’s A Good Buy
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.